HK Stock Market Move | HENLIUS(02696) rises nearly 4%; the U.S. bridging ASTRIDE study of H drug will make a major appearance as an oral presentation at the ESMO Congress

HENLIUS(02696) rose nearly 4%, up 2.43% as of press time, at HK$52.6, with a turnover of HK$14.4374 million. On the news front, on October 19, 2026 local time, the European Society for Medical Oncology (ESMO) Annual Congress published research abstracts. A total of 10 studies on HENLIUS' core product, the innovative anti-PD-1 monoclonal antibody H drug Hansizhuang (serplulimab, European trade name Hetronifly), were selected for this year's congress, among which the U.S. bridging ASTRIDE study will make a major appearance as an oral presentation, supplementing key clinical evidence in the U.S. native population for this anti-PD-1 monoclonal antibody, the world's first approved for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). It is worth noting that, as the world's first anti-PD-1 monoclonal antibody approved for first-line treatment of extensive-stage small cell lung cancer, H drug has now been approved for marketing in more than 50 countries and regions worldwide, covering nearly half of the global population, and has been included in local medical insurance payment systems in more than ten countries. Backed by the positive data from this U.S. bridging study, the internationalization process of H drug is expected to accelerate, bringing more immunotherapy options to patients with solid tumors worldwide.